Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

EsoCheck and EsoGuard for the Detection of Barrett's Esophagus in Patients without Chronic Gastroesophageal Reflux Disease Symptoms

Trial Status: active

This clinical trial assesses the EsoCheck and EsoGuard (EC/EG) test to detect Barrett’s esophagus (BE) in patients without gastroesophageal reflux disease (GERD) symptoms and have some risk factors for developing it. BE is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged by acid reflux. It is associated with an increased risk of developing esophageal cancer. The capsule balloon test called EC is a new Food and Drug Administration (FDA) approved method that is office based and examines the esophagus without using sedative medications or an endoscope. EG is a laboratory developed test that has an accuracy of 90% for BE in patients with GERD. EC/EG may help detect BE in patients without GERD symptoms.